13+ hour, 9+ min ago  (510+ words) Source: Dr. Ananda Ghosh (4/7/26) H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined…...